实现国际化里程碑突破 重药控股参投企业核心产品“沙美特罗替卡松吸入粉雾剂”获批上市

Group 1 - The FDA has approved a dry powder inhaler (DPI) developed by a Chinese pharmaceutical company, marking a significant entry into the international mainstream market for high-end complex formulations [1][4] - The approved product is a combination medication (bronchodilator and inhaled corticosteroid) used for the regular treatment of reversible airway obstructive diseases, including asthma in adults and children [1][4] - Runsheng Pharmaceutical, established in October 2014, focuses on the research and production of inhalation delivery systems for respiratory diseases and has a rich pipeline of products [1][4] Group 2 - Chongqing Yaoyou Pharmaceutical, a subsidiary of Zhongyao Holdings, has signed a licensing agreement with Pfizer for the exclusive development and commercialization rights of GLP-1R agonists, including YP05002, across all indications globally [2] - Yaoyou Pharmaceutical has received an upfront payment of $15 million from Pfizer as part of this agreement [2]